Expression and significance of cortactin and HDAC6 in human prostatic foamy gland carcinoma

Abstract

Cortactin, the cytoplasmic substrate of HDAC6, is known to play an actin cytoskeletal regulatory role which is implicated in the motility of cancer cells, and thus in cancer progression. Its activity is found to be regulated by HDAC6. However, the significance of cortactin and HDAC6 remains unclear in uncommon histologic variant human prostatic foamy gland carcinoma (PfCa). In this study, we aimed to identify the expression and potential role of cortactin and HDAC6 in PfCa. Therefore, 16 PfCa specimens containing 48 foci with distinctive lesions were collected to identify the status of cortactin and HDAC6 by immunohistochemistry. Their correlation between clinicopathological characteristics and prognostic values were further analysed. The effect of cortactin and HDAC6 on prostate cancer cell migration and invasion was then evaluated in IA8 cells. The results showed that expression of cortactin and HDAC6 was significantly higher in PfCa foci, compared to that of high-grade prostatic intraepithelial neoplasia (HGPIN) foci and benign foci (P < 0.05). Cortactin and HDAC6 were associated with poor prognosis of patients with PfCa (P < 0.05). Multivariable Cox regression analysis showed HDAC6 level was a significant prognostic factor for survival of patients with PfCa (β = 1.200, Wald value = 7.282, P = 0.007, 95% CI = 1.389-7.941, P < 0.01, β > 0). Both knocking down cortactin and inhibition of HDAC6 activity with tubacin reduced in vitro migration and invasion ability of IA8 cells substantially. Furthermore, HDAC6 has prognostic value for patients with PfCa. Dysregulation of cortactin and HDAC6 is implicated in the invasiveness and migration of prostate cancer cells.

A novel electrochemical nanobiosensor for the ultrasensitive and specific detection of femtomolar-level gastric cancer biomarker miRNA-106a

“…The recorded electrochemical signals presented in Table 2 demonstrate the upregulation of miR-106a in the serum samples of GC patients, which was anticipated according to the literature [2–3]. As references, the expression level of the serum miR-106a was simultaneously quantified by qRT-PCR after an extra RNA extraction step.…”

“…In spite of recent advances in diagnostic techniques and pre-operative management, the prognosis of patients with advanced disease is still poor, even in the developed countries [2]. The most commonly used tumor markers such as carcinoembryonic antigen (CEA) and cancer antigen 19-9 (CA19-9) have insufficient sensitivity and specificity, thus limiting their application in early diagnosis of GC [3]. Therefore, the establishment of novel strong specific biomarkers with sufficient sensitivity is an ideal strategy for improving the early detection of GC and the cure rates for patients.…”

“…There are already numerous reports that specify various miRNAs involved in GC tumorigenesis such as miR-106a [3]. miR-106a belongs to the miR-17 family and is an oncogenic member of miR-106a-363 cluster which is located on Xq26.2.…”

Diagnostic Performance of Cortactin in the Diagnosis of Oral Squamous Cell Carcinoma

“…A large number of researches had demonstrated that cortactin was correlated with the prognosis of various tumors, including OSCC [25][26][27]. In the study of Li et al, they reported that the negative expression of cortactin was an independent prognostic factor and had a survival advantage in epithelial ovarian cancer [28].…”

The emerging role of SPOP protein in tumorigenesis and cancer therapy

“…Histone deacetylase 6 (HDAC6) belongs to the HDACs family and is prominently involved in carcinogenesis and cancer progression [102,103]. Numerous studies have found that high expression of HDAC6 exists in several human cancers and is associated with a significantly poor prognosis in diseases such as breast cancer [104] and PrCa [105]. HDAC6 contains two functional catalytic domains and deacetylates many nonhistone oncogenic proteins [103].…”